Who owns XOMA Royalty Corporation - US (XOMA)? Elite investor 13F holders
2 tracked elite investors reported holding XOMA Royalty Corporation - US as of 2026-06-30, including Tudor Investment, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | XOMA ROYALTY CORPORATION | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3586618.00 USD | 84391.000000 | Shares | buy | Original filing |
| Ancora Advisors / Ancora Holdings | XOMA ROYALTY CORPORATION | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1317.00 USD | 31.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.